載入中
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
前收盤價
US$1.23
+US$0.11 · +9.82%
盤中時間採用ET。市場資料可能有所延遲。
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
日內區間
目前US$1.23
52週區間
目前US$1.23
盤中時間採用ET。市場資料可能有所延遲。
Lunai Bioworks Inc. (LNAI), formerly operating as Renovaro, is now dedicated to leveraging artificial intelligence for the creation of advanced medical treatments and the strengthening of biological defense systems. A significant project currently underway is the development of its specialized "Neurotoxicity Intelligence Technology."
日內區間
目前US$1.23
52週區間
目前US$1.23
營業利益
淨利
| 項目（USD） | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 | 2020會計年度 |
|---|---|---|---|---|---|
| 銷貨成本 | 12.91萬 USD | — | — | — | 39.14萬 USD |
| 毛利 | −12.91萬 USD | — | — | — | −39.14萬 USD |
| 研究與開發 | 53.74萬 USD | 270.88萬 USD | 416.52萬 USD | 837.28萬 USD | 1553.81萬 USD |
| 銷售、一般及管理費用 | 1788.01萬 USD | 2455.76萬 USD | 1531.82萬 USD | 1432.98萬 USD | 747.22萬 USD |
| 營業費用 | 1841.75萬 USD | 8163.93萬 USD | 3855.69萬 USD | 1.16億 USD | 2301.04萬 USD |
| 利息收入 | 11.63萬 USD | — | — | 12.2萬 USD | 1.32萬 USD |
| 利息支出 | 72.57萬 USD | 243.48萬 USD | 70.7萬 USD | 37.28萬 USD | 37.96萬 USD |
| 折舊和攤銷 | 12.91萬 USD | 12.19萬 USD | 11.35萬 USD | 12.36萬 USD | 39.14萬 USD |
| 營業利益 | −1854.66萬 USD | −8163.93萬 USD | −3855.69萬 USD | −1.16億 USD | −2340.18萬 USD |
| 淨利 | −1.78億 USD | −8842.58萬 USD | −3968.41萬 USD | −1.13億 USD | −2672.36萬 USD |
公司資料更新於 2026年10月11日。
報告持有此股票曝險的交易所交易基金。
AI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
